InfuSystem Holdings (INFU) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants Joe Dorame - Managing PartnerRichard DiIorio - CEOCarrie Lachance - President, COO & DirectorBarry Steele - Executive VP & CFO Conference Call Participants Brooks O'Neil - Senior Research AnalystTollef Kohrman - Associate AnalystJim Sidoti - AnalystAnderson Schock - Research Analyst Operator Good day, and welcome to the InfuSystem Holdings, Inc. Reports First Quarter twenty twenty five Financial Results Conference ...

Financial Data and Key Metrics Changes - Revenue for the first quarter of 2025 increased by 8.5% year-over-year, totaling $34.7 million, with adjusted EBITDA rising by 64% to $6.3 million [7][13][17] - Adjusted EBITDA margin improved to 18.2%, up from 12.1% in the previous year [10][17] - Operating cash flow reached $1.8 million, nearly four times higher than the prior year [9][18] Business Line Data and Key Metrics Changes - Patient Services segment revenue increased by 11.7%, contributing $2.2 million to the overall revenue growth, while Device Solutions segment revenue grew by 4% [13][14] - Oncology revenue rose by 10.3%, wound care treatment revenue surged by 133%, and pain management increased by 8.8% [14] - Device Solutions growth was driven by higher rental revenues, partially offset by lower biomedical services revenue [14] Market Data and Key Metrics Changes - The company is experiencing growth in various markets, particularly in oncology and wound care, indicating a robust demand for its services [14][22] - The company has established partnerships with major medical device companies, enhancing its market position [5][22] Company Strategy and Development Direction - The company aims to improve profitability and operational efficiencies while focusing on growth opportunities in wound care and biomed [21][24] - Future revenue growth is expected to be less capital-intensive, with a focus on leveraging existing infrastructure [19][24] - The company plans to complete a major technology system upgrade by early 2026, which is anticipated to enhance operational efficiencies [11][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong start to 2025 and a continuation of positive trends from 2024 [6][9] - The company expects full-year revenue growth of 8% to 10% and an adjusted EBITDA margin above 18.8% [17][24] - Management highlighted the importance of improving the profitability profile and aligning costs with growth opportunities [21][24] Other Important Information - The company incurred approximately $500,000 in expenses related to IT system upgrades during the first quarter [10][16] - Net capital expenditures for the first quarter were $2.6 million, significantly higher than the previous year's $400,000 [18][19] - The company maintains strong liquidity, with over $47.6 million available as of March 31, 2025 [20] Q&A Session Summary Question: Are the excellent results due to Carrie taking over? - Management clarified that the results are a culmination of years of work by Carrie and the team, not solely due to the leadership change [27] Question: Thoughts on tariff impact? - Management indicated limited exposure to tariffs, as most costs are related to personnel and depreciation rather than material purchases [31][33] Question: Opportunities in biomed services? - Management acknowledged the potential for growth in biomed services and is focused on leveraging existing infrastructure to attract additional customers [35] Question: Estimation of gross margins for the rest of the year? - Management suggested that the current gross margin may be a high watermark and expected stabilization rather than further increases [40] Question: Oncology business growth and future expectations? - Management noted that the recent growth was driven by improved revenue cycle processes and collections, with expectations for continued volume growth [46][47] Question: Device Solutions gross margin improvement? - Management attributed the growth to the rental business and indicated a positive outlook for future margins in this segment [51][53] Question: Impact of proposed budget cuts by the new administration? - Management expressed confidence that the company is well-positioned in the home care market and does not foresee significant risks from budget cuts [54][56] Question: IT upgrade costs and timeline? - Management confirmed that the $2.5 million in costs for the IT upgrade will taper off significantly after the first quarter of 2026 [57][66] Question: Tax rate and cash tax payments? - Management explained that the high tax rate was due to non-deductible expenses and that most tax provisions are deferred, with minimal cash tax payments currently [58][60]

Financial Data and Key Metrics Changes - The company reported a 7% increase in net revenue for Q4 2024, totaling $33.8 million, compared to the prior year [18] - Gross margins increased by 2% year-over-year to 52.2% [8] - Operating income rose by 69% to $6.9 million, while adjusted EBITDA increased by 13% to $25.3 million, with an adjusted EBITDA margin of 18.8% for the full year [9][10] Business Line Data and Key Metrics Changes - Revenue growth was observed across almost all business lines, with oncology and pain management increasing by 6.1% and 14.7% respectively [11] - Equipment rentals in device solutions grew by 13.6%, and equipment sales increased by 20.6% due to a significant transaction in Q3 [11] - Advanced wound care revenue surged by 342%, while the wound care segment overall was below expectations due to a strategic pause in onboarding new initiatives [12][19] Market Data and Key Metrics Changes - The company noted a strong demand for advanced wound care products and biomed services, indicating a ripe opportunity for growth in these areas [41] - The addressable market for Chemo Mouthpiece is estimated to be around $500 to $600 million, highlighting significant potential for revenue generation [67] Company Strategy and Development Direction - The company aims for revenue growth of 8% to 10% in 2025, with adjusted EBITDA margins expected to exceed 18.8% [34] - Focus on less capital-intensive revenue sources, such as biomedical services and advanced wound care supplies, is expected to drive future growth [26][34] - The company is strategically pausing some wound care initiatives to ensure quality and alignment with existing resources before ramping up in 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth across all business lines in 2025, particularly in advanced wound care and biomed [43] - The sales cycle for Chemo Mouthpiece is anticipated to gain momentum in the coming months, with clinical studies expected to enhance market adoption [49][70] - The company expects to see benefits from improvements in the referral process throughout 2025, with gradual enhancements in operational efficiency [55] Other Important Information - The effective tax rate for Q4 2024 was reported at 59%, primarily due to equity compensation deductions and other non-cash tax expenses [22][23] - The company’s net debt decreased to $23.3 million, with strong liquidity reserves of over $51 million as of December 31, 2024 [27][28] Q&A Session Summary Question: Growth expectations for Advanced Wound Care products - Management indicated that Advanced Wound Care is expected to drive most of the growth in 2025, with significant opportunities from DME partners [41][43] Question: Feedback on Chemo Mouthpiece from oncology centers - Management noted growing interest and small orders for Chemo Mouthpiece, with expectations for broader adoption following the publication of clinical studies [46][49] Question: Improvements in the referral process - Management explained that improvements in the referral process will ramp throughout the year, with some benefits expected in Q1 [53][55] Question: Addressable market for Chemo Mouthpiece and Dignitana - Management stated that Chemo Mouthpiece has a large addressable market, while Dignitana represents a smaller but significant opportunity [66][67] Question: Factors contributing to EBITDA margin improvement - Management highlighted continued efficiencies in biomed and growth in other areas as key contributors to improved EBITDA margins [72][75]